Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Lepu Medical Leads $40 Million Financing for Rgenix, a New York Biopharma

publication date: Oct 10, 2018

Lepu Medical Technology of Beijing led a $40 million Series C round for New York-based Rgenix. Lepu contributed $12.5 million to the round and said it "looks forward to exploring possible collaborative opportunities with Rgenix as part of our goal to develop further in the oncology market together." Rgenix will use the proceeds to support Phase Ib and Phase II clinical trials of RGX-104, its small molecule immunotherapy and lead product, plus development of a molecule that suppresses gastrointestinal cancer progression and several discovery stage programs.More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Other Events

www.chinatrialsevent.com

Shanghai,China

November 7–9, 2018

ChinaBio members can get a 20% discount with the promotion code"chinabio18"